

Sanofi-aventis and *Medicines for Malaria Venture* Enter Into Collaboration to Fight Malaria

- Goal is to accelerate Research and Development of New Antimalarial Drugs -

Paris, France, Geneva, Switzerland – October 22, 2008 – Sanofi-aventis, and *Medicines for Malaria Venture* announced today that they have entered into a joint agreement to speed up the research and development of new treatments for malaria, an often fatal infectious disease in developing countries that particularly affects pregnant women and children under the age of five.

Medicines for Malaria Venture (MMV) is a not-for-profit virtual research and development organization dedicated to reducing the burden of malaria.

Under the terms of the agreement, sanofi-aventis will share information with MMV on its malaria drugs portfolio. The portfolio includes a licensed fixed-dose combination of artesunate and amodiaquine (Coarsucam[®], or “ASAQ”), co-developed with the *Drugs for Neglected Diseases initiative* (DNDi) and several compounds resulting from research collaborations with French academic institutions and start-ups. These compounds which are today at various stages of development include: ferroquine with the *Université des Sciences et Technologies de Lille*, a trioxaquine compound with *Palumed* (Toulouse) and a bis-thiazolium compound with the *Centre National pour la Recherche Scientifique* (Montpellier). In addition, a research program for new antimalarials has been initiated within sanofi-aventis that will screen a very large number of candidate compounds.

MMV and sanofi-aventis will set up working groups to review each of these projects and define specific collaborative actions between the two organizations for their further development.

“Joining forces with MMV in the search for innovative antimalarial drugs will help us stay ahead in the race against parasites that will sooner or later develop resistances to existing treatments. This new partnership will enable us to mobilize each organization’s expertise, resources and know-how and create synergies that will speed up the availability of novel medicines for malaria patients” said Marc Cluzel, Senior Vice-President R&D at sanofi-aventis.

“MMV is delighted to be working with an innovative organization such as sanofi-aventis that is active in the fight against malaria. Malaria kills up to one million people annually, and the majority of those who die are children under five and pregnant women,” said Dr. Chris Hentschel, president and chief executive officer of MMV. *“If we are to achieve eradication in the long term we have to start with developing new antimalarials agents to stop this unacceptable loss of life. With the help of sanofi-aventis the pipeline of new molecules effective against malaria will be made more robust so that we can develop the next generation of powerful treatments.”*

About Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) was established in 1999 as a not-for-profit organization created to discover, develop and deliver safe, effective and affordable antimalarial drugs through effective public-private partnerships. MMV's vision is a world in which affordable and effective medicines will cure and protect the millions at risk of malaria and help to ultimately eradicate this terrible disease.

MMV is currently managing the largest—ever portfolio of antimalarial projects in collaboration with over 100 pharmaceutical, academic, and endemic-country partners. Its robust portfolio of around 40 projects includes 19 completely new classes of compounds in the discovery phase. Of the five projects in clinical development, three are artemisinin combination therapies (ACTs), which will be registered by stringent regulatory authorities and are expected to gain market authorization between 2008 and 2010.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts :

Sanofi-aventis

François Bompert

Tel: +33 1 41 24 53 45

Mobile: +33 6 08 25 61 67

E-mail : francois.bompert@sanofi-aventis.com

MMV

Ms. Jaya Banerji

Tel: +41 (22) 799 40 71

Mobile: +41 (79) 707 7181

E-mail: janerji@mmv.org